Aflibercept anti-vascular endothelial growth factor therapy in vitrectomized eyes with neovascular age-related macular degeneration.
作者信息
Jung Jesse J, Hoang Quan V, Arain Mohammad Z Y, Chang Stanley
机构信息
Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Vitreous Retina Macula Consultants of New York, New York, NY, USA.
出版信息
Acta Ophthalmol. 2016 May;94(3):e249-50. doi: 10.1111/aos.12840. Epub 2015 Sep 24.
Abstract
摘要
相似文献
1
Aflibercept anti-vascular endothelial growth factor therapy in vitrectomized eyes with neovascular age-related macular degeneration.阿柏西普抗血管内皮生长因子疗法用于玻璃体切除术后的新生血管性年龄相关性黄斑变性患者。
Acta Ophthalmol. 2016 May;94(3):e249-50. doi: 10.1111/aos.12840. Epub 2015 Sep 24.
2
THE INFLUENCE OF VITREOMACULAR ADHESION ON OUTCOMES AFTER AFLIBERCEPT THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.玻璃体黄斑粘连对阿柏西普治疗新生血管性年龄相关性黄斑变性疗效的影响
Retina. 2015 Oct;35(10):1951-6. doi: 10.1097/IAE.0000000000000587.
3
Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.抗 VEGF 药物治疗后脉络膜新生血管性年龄相关性黄斑变性患者仍存在黄斑中心凹下积液行玻璃体腔注射阿柏西普的疗效观察
Retina. 2013 Sep;33(8):1605-12. doi: 10.1097/IAE.0b013e31828e8551.
4
LASER RESENSITIZATION OF MEDICALLY UNRESPONSIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Efficacy and Implications.医学上无反应的新生血管性年龄相关性黄斑变性的激光再敏化：疗效与启示
Retina. 2015 Jun;35(6):1184-94. doi: 10.1097/IAE.0000000000000458.
5
PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.阿柏西普治疗对雷珠单抗耐药的新生血管性年龄相关性黄斑变性患者色素上皮脱离的反应：时间进程和药物效应
Retina. 2016 May;36(5):881-8. doi: 10.1097/IAE.0000000000000813.
6
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.阿柏西普治疗对贝伐单抗和雷珠单抗抵抗的渗出性年龄相关性黄斑变性。
Am J Ophthalmol. 2013 Jul;156(1):15-22.e1. doi: 10.1016/j.ajo.2013.02.017. Epub 2013 May 22.
7
Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.阿柏西普治疗新生血管性年龄相关性黄斑变性的中心凹下脉络膜厚度：12 个月结果。
Ophthalmology. 2016 Mar;123(3):617-24. doi: 10.1016/j.ophtha.2015.10.039. Epub 2015 Dec 11.
8
Experience With Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration.阿柏西普治疗新生血管性年龄相关性黄斑变性的经验
Ophthalmic Surg Lasers Imaging Retina. 2015 May;46(5):542-9. doi: 10.3928/23258160-20150521-05.
9
Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration.使用阿柏西普双月治疗方案治疗新生血管性年龄相关性黄斑变性时色素上皮脱离和视网膜积液的波动情况
Ophthalmologica. 2016;235(1):42-8. doi: 10.1159/000441428. Epub 2015 Nov 6.
10
INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX).玻璃体黄斑界面在采用治疗与延长治疗方案治疗年龄相关性黄斑变性（VINTREX）中对抗血管内皮生长因子治疗的影响
Retina. 2015 Sep;35(9):1757-64. doi: 10.1097/IAE.0000000000000663.
引用本文的文献
1
Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema.糖尿病性黄斑水肿患者从阿柏西普转换为法西单抗后的真实世界转归
Invest Ophthalmol Vis Sci. 2024 Dec 2;65(14):46. doi: 10.1167/iovs.65.14.46.
2
Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye.玻璃体腔注射布罗珠单抗治疗玻璃体切除术后眼的新生血管性年龄相关性黄斑变性
Case Rep Ophthalmol. 2022 Sep 30;13(3):736-743. doi: 10.1159/000526568. eCollection 2022 Sep-Dec.
3
Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration.新生血管性年龄相关性黄斑变性患者黄斑下和/或玻璃体积血行玻璃体切除术后的长期预后
J Ophthalmol. 2021 Nov 2;2021:2963822. doi: 10.1155/2021/2963822. eCollection 2021.
4
Efficacy of anti-vascular endothelial growth factor agents for treating neovascular age-related macular degeneration in vitrectomized eyes.抗血管内皮生长因子药物治疗玻璃体切割术后新生血管性年龄相关性黄斑变性的疗效。
PLoS One. 2021 Jun 10;16(6):e0252006. doi: 10.1371/journal.pone.0252006. eCollection 2021.
5
Eyes that Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion.不符合年龄相关性黄斑变性临床试验纳入标准的眼部情况：真实世界患者群体的比例及排除原因。
J Ophthalmol. 2021 Apr 17;2021:6635467. doi: 10.1155/2021/6635467. eCollection 2021.
本文引用的文献
1
Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye.在接受玻璃体切割术的眼中，使用阿柏西普成功治疗贝伐单抗单次治疗失败后的新生血管性年龄相关性黄斑变性。
Clin Ophthalmol. 2014 Oct 17;8:2129-31. doi: 10.2147/OPTH.S73265. eCollection 2014.
2
Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes.玻璃体内注射雷珠单抗的眼内药代动力学：玻璃体切割眼与非玻璃体切割眼比较。
Invest Ophthalmol Vis Sci. 2014 Jan 29;55(1):567-73. doi: 10.1167/iovs.13-13054.
3
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.玻璃体内注射阿柏西普治疗新生血管性年龄相关性黄斑变性：VIEW 研究的 96 周结果。
Ophthalmology. 2014 Jan;121(1):193-201. doi: 10.1016/j.ophtha.2013.08.011. Epub 2013 Sep 29.
4
Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy.玻璃体切除和晶状体切除术后玻璃体内贝伐单抗和雷珠单抗的解剖和药代动力学特性。
Retina. 2013 May;33(5):946-52. doi: 10.1097/IAE.0b013e3182753b12.
5
Diffusion characteristics of vitreous humour and saline solution follow the Stokes Einstein equation.玻璃体液和盐溶液的扩散特性遵循斯托克斯-爱因斯坦方程。
Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1677-84. doi: 10.1007/s00417-009-1141-3. Epub 2009 Jul 29.
6
Predicted biological activity of intravitreal VEGF Trap.玻璃体内注射VEGF Trap的预测生物学活性。
Br J Ophthalmol. 2008 May;92(5):667-8. doi: 10.1136/bjo.2007.134874. Epub 2008 Mar 20.
Zotero 插件